Compare BridgeBio Pharma Inc (BBIO) vs General Mills, Inc. (GIS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs General Mills, Inc. — how do they compare? BridgeBio Pharma Inc trades at $82.48 (market cap $16.46B), while General Mills, Inc. trades at $37.09 (market cap $19.46B). The key difference: General Mills, Inc. is the larger of the two by market cap, and General Mills, Inc. pays a 6.69% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | GIS | |
|---|---|---|
Market Cap | $16.46B | $19.46B |
Sector | Health | Consumer Staples |
52-Week High | $90.17 | $51.27 |
52-Week Low | $44.81 | $32.17 |
Enterprise Value | $18.02B | $32.95B |
Dividend Yield | — | 6.69% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $83.08, down 3.27% today, near its 52-week high. The stock shows bullish technical momentum with strong moving averages, while fundamentals reveal rapid revenue growth to $502M in 2025 but persistent losses with a -144.4% net margin. Recent news highlights regulatory approvals for acoramidis and a $1B preferred equity raise to fund launches, driving positive sentiment despite earnings misses.
Outlook remains speculative with high execution risk; analyst consensus is strongly bullish (92% buy) targeting $104.57, but profitability challenges and heavy cash burn require successful pipeline commercialization to justify valuation. Key near-term catalysts include FDA decisions on BBP-418 and encaleret in 2026.
General Mills (GIS) trades at $36.60, up 1.05% with a bullish technical signal. The stock shows mixed earnings performance with recent Q2 2026 beating estimates, but faces declining revenue and negative net income margin. Analyst consensus is predominantly hold with a $36.14 price target. Cash flow trends show modest improvement, though debt levels have risen to 45% of assets. Recent news highlights cost-saving initiatives and innovation focus amid soft consumer demand.
Outlook remains cautious due to sales pressure and margin challenges, but valuation at 9.23 P/E suggests potential value. Key opportunities include $3 billion savings target by 2030 and brand investments. Risks involve persistent demand weakness, private label competition, and high debt burden. Investors should weigh cost-cutting benefits against top-line headwinds for recovery prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About General Mills, Inc.
General Mills is a leading global packaged food company that produces snacks, cereal, convenient meals, yogurt, dough, baking mixes and ingredients, pet food, and superpremium ice cream. Its largest brands are Nature Valley, Cheerios, Old El Paso, Yoplait, Pillsbury, Betty Crocker, BLUE, and Haagen-Dazs. In fiscal 2022, 77% of its revenue was derived from the United States, although the company also operates in Canada, Europe, Australia, Asia, and Latin America. While most of General Mills' products are sold through retail stores to consumers, the company also sells products into the food-service channel and the commercial baking industry.
Read more on GIS →
